Additionally, drugs targeting JAK/STAT signaling may effectively assist in the treatment of COVID-19 by restricting cytokine storm syndrome (Luo et al., 2020; Solimani et al., 2021), and three severe COVID-19 cases are reported to be observed to have sustained improvements in outcome with ruxolitinib, which targets the JAK/STAT pathway (Rojas and Sarmiento, 2021). Here, SOAT1 is linked to COVID-19.